A pan-cancer analysis of the oncogenic and immunological roles of apolipoprotein F (APOF) in human cancer.
Apolipoprotein F
Breast invasive carcinoma
Kidney chromophobe
Liver hepatocellular carcinoma
Pan-cancer
Prognosis
Prostate adenocarcinoma
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
14 Jun 2023
14 Jun 2023
Historique:
received:
31
12
2022
accepted:
03
06
2023
medline:
15
6
2023
pubmed:
14
6
2023
entrez:
13
6
2023
Statut:
epublish
Résumé
Apolipoprotein F (APOF) has been less studied in cancers. Thus, we aimed to perform a pan-cancer analysis of the oncogenic and immunological effects of APOF on human cancer. A standardized TCGA pan-cancer dataset was downloaded. Differential expression, clinical prognosis, genetic mutations, immune infiltration, epigenetic modifications, tumor stemness and heterogeneity were analyzed. We conducted all analyses through software R (version 3.6.3) and its suitable packages. Overall, we found that the common cancers differentially expressed between tumor and normal samples and prognostic-associated were BRCA, PRAD, KIRP, and LIHC in terms of overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS). The pan-cancer Spearman analysis showed that the mRNA expression of APOF was negatively correlated with four tumor stemness indexes (DMPss, DNAss, ENHss, and EREG-METHss) with statistical significance for PRAD and was positively correlated for LIHC. In terms of BRCA and PRAD patients, we found negative correlation of APOF with TMB, MSI, neo, HRD and LOH. The mutation frequencies of BRCA and LIHC were 0.3%. APOF expression was negatively correlated with immune infiltration and positively correlated with tumor purity for PRAD patients. The mRNA expression of APOF was negatively associated with most TILs for LIHC, B cells, CD4+ T cells, neutrophils, macrophages and dendritic cells, but was positively associated with CD8+ T cells. Our pan-cancer study offered a relatively comprehensive understanding of the roles of APOF on BRCA, PRAD, KIRP, and LIHC.
Sections du résumé
BACKGROUND
BACKGROUND
Apolipoprotein F (APOF) has been less studied in cancers. Thus, we aimed to perform a pan-cancer analysis of the oncogenic and immunological effects of APOF on human cancer.
METHODS
METHODS
A standardized TCGA pan-cancer dataset was downloaded. Differential expression, clinical prognosis, genetic mutations, immune infiltration, epigenetic modifications, tumor stemness and heterogeneity were analyzed. We conducted all analyses through software R (version 3.6.3) and its suitable packages.
RESULTS
RESULTS
Overall, we found that the common cancers differentially expressed between tumor and normal samples and prognostic-associated were BRCA, PRAD, KIRP, and LIHC in terms of overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS). The pan-cancer Spearman analysis showed that the mRNA expression of APOF was negatively correlated with four tumor stemness indexes (DMPss, DNAss, ENHss, and EREG-METHss) with statistical significance for PRAD and was positively correlated for LIHC. In terms of BRCA and PRAD patients, we found negative correlation of APOF with TMB, MSI, neo, HRD and LOH. The mutation frequencies of BRCA and LIHC were 0.3%. APOF expression was negatively correlated with immune infiltration and positively correlated with tumor purity for PRAD patients. The mRNA expression of APOF was negatively associated with most TILs for LIHC, B cells, CD4+ T cells, neutrophils, macrophages and dendritic cells, but was positively associated with CD8+ T cells.
CONCLUSIONS
CONCLUSIONS
Our pan-cancer study offered a relatively comprehensive understanding of the roles of APOF on BRCA, PRAD, KIRP, and LIHC.
Identifiants
pubmed: 37312170
doi: 10.1186/s40001-023-01156-w
pii: 10.1186/s40001-023-01156-w
pmc: PMC10265855
doi:
Substances chimiques
apolipoprotein F
0
Apolipoproteins
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
190Subventions
Organisme : programs from Science and Technology Department of Sichuan Province
ID : 2020YFSY0024
Organisme : National Natural Science Foundation of China
ID : 82170432
Organisme : National Key Research and Development Program of China
ID : 2021YFC2009303
Organisme : Project of Health Commission of Sichuan Province
ID : 21PJ041
Organisme : the Key Research and Development Support Plan of Chengdu Science and Technology Bureau
ID : 2022-YF05-01568-SN
Informations de copyright
© 2023. The Author(s).
Références
BMC Cancer. 2014 Feb 26;14:132
pubmed: 24571647
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
J Hepatol. 2016 Sep;65(3):579-88
pubmed: 27261415
Cancer Cell Int. 2020 Apr 22;20:130
pubmed: 32336950
Front Immunol. 2022 Jan 27;13:777724
pubmed: 35154101
Asian J Androl. 2023 Mar-Apr;25(2):208-216
pubmed: 36412461
Cell. 2019 Oct 31;179(4):813-827
pubmed: 31675495
Lab Invest. 2008 Oct;88(10):1049-56
pubmed: 18762779
Mol Cell Proteomics. 2014 Feb;13(2):397-406
pubmed: 24309898
PLoS One. 2012;7(2):e31616
pubmed: 22363685
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Aging Dis. 2022 Jul 11;13(4):1063-1091
pubmed: 35855334
J Clin Invest. 2016 Oct 3;126(10):3852-3867
pubmed: 27599291
Cancer Med. 2019 Nov;8(16):7032-7043
pubmed: 31573738
Front Oncol. 2022 Dec 12;12:1042118
pubmed: 36578929
J Lipid Res. 2008 Jul;49(7):1529-37
pubmed: 18369235
Prostate. 2023 May 8;:
pubmed: 37154584
J Lipid Res. 2004 Sep;45(9):1594-607
pubmed: 15145983
Ital J Biochem. 2004 Dec;53(4):169-82
pubmed: 15997910
Oncotarget. 2016 Oct 25;7(43):70654-70668
pubmed: 27683106
J Lipid Res. 2009 Apr;50(4):676-84
pubmed: 19008550
Nutrients. 2014 Dec 22;6(12):6095-109
pubmed: 25533015
PLoS One. 2017 Oct 31;12(10):e0186649
pubmed: 29088295
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Mar;1865(3):158583
pubmed: 31812787
N Engl J Med. 2002 Apr 18;346(16):1221-31
pubmed: 11961152
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Cancer Res. 2013 Aug 1;73(15):4722-31
pubmed: 23749645
J Lipid Res. 1994 May;35(5):836-47
pubmed: 8071606
Hepatology. 2023 Apr 1;77(4):1287-1302
pubmed: 35735979
J Lipid Res. 2008 Jan;49(1):127-35
pubmed: 17901467
Breast Cancer Res Treat. 2003 Mar;78(2):167-78
pubmed: 12725417
Oncogene. 2013 Feb 21;32(8):961-7
pubmed: 22469977
Exp Hematol Oncol. 2022 Sep 15;11(1):55
pubmed: 36109820
FEBS Open Bio. 2014 Sep 02;4:741-5
pubmed: 25349778
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Asian J Androl. 2023 Mar-Apr;25(2):223-229
pubmed: 36124532
Front Oncol. 2022 Apr 06;12:858479
pubmed: 35463369
J Biol Chem. 2011 Aug 5;286(31):27389-98
pubmed: 21646352
Arterioscler Thromb Vasc Biol. 2001 Oct;21(10):1642-9
pubmed: 11597939
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Geroscience. 2021 Apr;43(2):487-505
pubmed: 32529593
Nat Rev Immunol. 2022 Jul;22(7):429-443
pubmed: 34741169
Front Immunol. 2021 Jul 02;12:687975
pubmed: 34276676
Bioinformatics. 2019 Oct 15;35(20):4200-4202
pubmed: 30903160
Nat Metab. 2021 Dec;3(12):1596-1607
pubmed: 34931080
Eur Urol. 2013 Jan;63(1):178-9
pubmed: 23218490
Immunology. 2022 Jun;166(2):197-209
pubmed: 35271752
Biochemistry. 1978 Mar 21;17(6):1032-6
pubmed: 204339
Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):40-6
pubmed: 19008531
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
Immunology. 2023 Feb;168(2):199-202
pubmed: 35146758
Front Cell Dev Biol. 2022 Feb 10;10:803766
pubmed: 35223835
Cancer Genomics Proteomics. 2017 01-02;14(1):35-51
pubmed: 28031236
Biochem Biophys Res Commun. 2013 Nov 29;441(4):880-5
pubmed: 24211198
Exp Hematol Oncol. 2022 Oct 20;11(1):76
pubmed: 36266657
Curr Opin Lipidol. 2020 Aug;31(4):194-199
pubmed: 32520778
Cancer Res. 2004 Mar 1;64(5):1834-42
pubmed: 14996747
J Lipid Res. 2011 Dec;52(12):2262-2271
pubmed: 21937674
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Alzheimers Dement. 2018 Feb;14(2):230-242
pubmed: 28945989
Int J Colorectal Dis. 2013 Jun;28(6):751-66
pubmed: 23296401
Oral Oncol. 2019 Mar;90:54-66
pubmed: 30846177
Curr Opin Clin Nutr Metab Care. 2006 Jul;9(4):358-65
pubmed: 16778563
J Lipid Res. 2009 Apr;50 Suppl:S189-94
pubmed: 19064999
J Lipid Res. 2010 Dec;51(12):3524-32
pubmed: 20855565
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
J Biol Chem. 1999 Jan 15;274(3):1814-20
pubmed: 9880564
Front Oncol. 2022 Jan 12;11:805571
pubmed: 35096608
Dev Comp Immunol. 2017 Feb;67:464-470
pubmed: 27640368
Front Immunol. 2022 Feb 24;13:839362
pubmed: 35280985
Front Immunol. 2023 Apr 20;14:1113756
pubmed: 37153545
J Clin Oncol. 2011 Apr 20;29(12):1592-8
pubmed: 21422422
Eur J Med Res. 2023 May 13;28(1):172
pubmed: 37179366
Front Oncol. 2021 Sep 13;11:732743
pubmed: 34589434
Nat Rev Urol. 2023 May 17;:
pubmed: 37198266
Aging Dis. 2023 Aug 1;:
pubmed: 37163421
Cardiovasc Diabetol. 2022 Feb 7;21(1):21
pubmed: 35130909
Aging Dis. 2022 Apr 1;13(2):423-432
pubmed: 35371612
Gastroenterol Rep (Oxf). 2019 Apr 21;7(5):354-360
pubmed: 31687155
PLoS One. 2020 Jun 15;15(6):e0233974
pubmed: 32542012
Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2473-8
pubmed: 25675507
J Lipid Res. 2019 Nov;60(11):1868-1879
pubmed: 31511396
J Transl Med. 2022 Jun 3;20(1):252
pubmed: 35658892
Aging Dis. 2023 May 09;:
pubmed: 37199595
Nat Commun. 2018 Sep 27;9(1):3957
pubmed: 30262900
Biochimie. 2015 May;112:1-9
pubmed: 25726912
Nat Commun. 2013;4:2612
pubmed: 24113773
Mol Endocrinol. 2006 Oct;20(10):2265-77
pubmed: 16455816
Exp Hematol Oncol. 2023 Jan 12;12(1):8
pubmed: 36635777
Am J Cancer Res. 2022 Aug 15;12(8):3811-3828
pubmed: 36119834
Cell. 2018 Apr 5;173(2):338-354.e15
pubmed: 29625051
Expert Opin Investig Drugs. 2010 Apr;19 Suppl 1:S79-89
pubmed: 20374034